GleamWall
中文EN

AWHL Aspira Women's Health Inc.

In Vitro & In Vivo Diagnostic Substances · OTC · SEC CIK 926617 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY112.2%
TTM net income YoY55.8%
TTM EPS YoY71.4%
Revenue 3-yr CAGR-67.5%
Net income 3-yr CAGR—

Margins

Gross margin1,481.2%
Operating margin-2,079.9%
Net margin-1,520.4%
FCF margin—
EBITDA margin-2,026.1%

Returns

ROE—
ROA-87.8%
ROIC (approx.)—
Asset turnover0.06x

Leverage & solvency

Liabilities / assets291.9%
Debt / equity—
Current ratio0.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.08x
Accruals ratio6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$11,000$17,000$32,000$254,000$89,000$169,000$0-$2.83M
Cost of revenue$869,000$915,000$896,000$790,000$922,000$870,000$719,000$860,000
Gross profit$1.01M$1.13M$1.07M$1.44M$1.38M$1.53M$1.56M$1.49M
R&D expense$589,000$692,000$1.23M$462,000$739,000$704,000$973,000$500,000
SG&A expense$1.15M$1.71M$1.50M$1.72M$1.54M$1.96M$2.74M$2.44M
Operating income-$1.21M-$1.83M-$2.20M-$1.28M-$1.58M-$1.81M-$3.24M-$3.43M
Pretax income$339,000—$676,000-$3.37M-$4.89M—-$1.85M—
Net income$339,000-$2.42M$676,000-$3.37M-$4.89M-$2.67M-$1.85M-$1.39M
EBITDA-$1.16M-$1.79M-$2.16M-$1.25M-$1.53M-$1.80M-$3.23M-$3.42M
EPS (basic)0.01-0.050.02—-0.13-0.07-0.09—
EPS (diluted)0.01-0.05-0.05—-0.13-0.07-0.09—
Weighted avg. shares (diluted)47.58M44.25M45.77M—36.39M35.56M21.59M—
Banking
Net interest income-$330,000-$227,000-$231,000-$1,000-$13,000-$13,000-$14,000-$13,000
Balance sheet
Cash & equivalents$12,000$477,000$1.34M$1.75M$3.81M$1.54M$3.31M$1.77M
Receivables$1.44M$1.49M$1.42M$1.21M$1.32M$1.28M$1.10M$990,000
Inventory$229,000$231,000$292,000$256,000$282,000$273,000$260,000$326,000
Current assets$1.85M$2.80M$3.79M$4.06M$5.83M$3.69M$5.39M$4.18M
PP&E, net$367,000$179,000$38,000$47,000$44,000$44,000$56,000$69,000
Intangibles$214,000$246,000$278,000$310,000$343,000———
Total assets$3.58M$4.43M$5.09M$5.46M$7.30M$4.93M$6.72M$5.49M
Current liabilities$6.09M$5.34M$5.59M$3.46M$4.20M$4.10M$3.79M$5.47M
Short-term debt$152,000$199,000$238,000$236,000$234,000$232,000$231,000$229,000
Long-term debt$948,000$961,000$980,000$1.04M$1.10M$1.16M$1.22M$1.28M
Total debt$1.10M$1.16M$1.22M$1.28M$1.33M$1.39M$1.45M$1.51M
Total liabilities$10.45M$11.69M$11.29M$12.39M$11.64M$7.62M$6.78M$8.05M
Shareholders' equity-$6.87M-$7.26M-$6.21M-$6.93M-$4.34M-$2.69M-$60,000-$2.56M
Net debt$1.09M$683,000-$126,000-$478,000-$2.48M-$153,000-$1.86M-$262,000
Shares outstanding46.63M46.63M43.50M43.48M42.66M35.64M35.23M17.41M
Cash flow statement
Operating cash flow-$794,000-$2.01M-$359,000-$1.98M-$212,000-$1.73M-$3.10M-$1.02M
Capital expenditure$207,000——$8,000———$0
Free cash flow-$1.00M——-$1.99M———-$1.02M
Investing cash flow-$207,000——-$8,000———$0
Financing cash flow$536,000$1.29M-$52,000-$65,000$2.87M-$33,000$4.64M$657,000
Depreciation & amortization$51,000$40,000$40,000$38,000$50,000$11,000$13,000$14,000
Stock-based compensation$50,000$19,000$42,000$376,000$37,000$15,000$103,000$630,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.